









市场行情
/
股票
/
nasdaq-nnnn
/

Anbio Biotechnology

NNNN

32.350USD

+2.100+6.94%

收盘 12/19, 16:00（美东）报价延迟15分钟

4.65B总市值

1939.45市盈率 TTM



Anbio Biotechnology

32.350

+2.100+6.94%

概览公司财务分析

概览

公司

财务

分析

关于 Anbio Biotechnology 公司

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Anbio Biotechnology简介



公司代码NNNN

公司名称Anbio Biotechnology

上市日期Feb 19, 2025

CEOLau (Michael)

员工数量27

证券类型Ordinary Share

年结日Feb 19

公司地址Friedrich-Ebert-Anlage 49

城市FRANKFURT AM MAIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Germany

邮编60308

电话4916096247281

网址https://anbiobiotechnology.com/

公司代码NNNN

上市日期Feb 19, 2025

CEOLau (Michael)

Anbio Biotechnology公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Nancy Hartzler

Independent Director

Mr. David Hsu

Independent Director

Mr. Kenneth Li

Independent Director

Mr. Michael Lau

Chief Executive Officer

Ms. Suki Song

Chief Financial Officer

Mr. Cany Xu

Executive Director

Mr. Chris Tiantian

Chief Business Officer

名称

名称/职务

职务

持股

持股变动

Ms. Nancy Hartzler

Independent Director

Mr. David Hsu

Independent Director

Mr. Kenneth Li

Independent Director

Mr. Michael Lau

Chief Executive Officer

Ms. Suki Song

Chief Financial Officer

Mr. Cany Xu

Executive Director

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2023

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

European Union

5.62M

68.64%

South America

1.48M

18.02%

Asia Pacific

509.17K

6.22%

Other Regions

472.38K

5.77%

North America

110.51K

1.35%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月4日周四

持股股东

股东类型

持股股东

占比

Northwestern Mutual Capital, LLC

4.78%

CVC Investment

4.78%

Geode Capital Management, L.L.C.

0.06%

Marshall Wace LLP

0.02%

Morgan Stanley & Co. LLC

0.02%

其他

90.33%

持股股东

占比

Northwestern Mutual Capital, LLC

4.78%

CVC Investment

4.78%

Geode Capital Management, L.L.C.

0.06%

Marshall Wace LLP

0.02%

Morgan Stanley & Co. LLC

0.02%

其他

90.33%

股东类型

持股股东

占比

Investment Advisor

4.80%

Corporation

4.78%

Investment Advisor/Hedge Fund

0.08%

Research Firm

0.03%

Hedge Fund

0.02%

Venture Capital

0.02%

其他

90.28%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

2.13M

4.85%

+2.06M

2025Q2

4.27M

9.72%

+4.25M

2025Q1

4.27M

9.72%

+4.27M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Northwestern Mutual Capital, LLC

2.10M

4.78%

+2.10M

Feb 19, 2025

CVC Investment

2.10M

4.78%

+2.10M

Feb 19, 2025

Geode Capital Management, L.L.C.

17.13K

0.04%

+70.00

+0.41%

Jun 30, 2025

Marshall Wace LLP

-43.63K

-100.00%

Jun 30, 2025

Morgan Stanley & Co. LLC

400.00

+400.00

Jun 30, 2025

BNP Paribas Securities Corp. North America

1.26K

+1.26K

Jun 30, 2025

UBS Financial Services, Inc.

10.70K

0.02%

+4.96K

+86.39%

Jun 30, 2025

持股ETF



机构名称

占比

暂无数据

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Anbio Biotechnology的前五大股东是谁？



Anbio Biotechnology 的前五大股东如下：
Northwestern Mutual Capital, LLC持有股份：2.10M，占总股份比例：4.78%。
CVC Investment持有股份：2.10M，占总股份比例：4.78%。
Geode Capital Management, L.L.C.持有股份：17.13K，占总股份比例：0.04%。
Marshall Wace LLP持有股份：0.00，占总股份比例：0.00%。
Morgan Stanley & Co. LLC持有股份：400.00，占总股份比例：0.00%。